MDxHealth SA (0O8G.L)
| Previous close | 0.7740 |
| Open | 0.8200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.8200 - 0.8200 |
| 52-week range | 0.8200 - 0.8200 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 453,385 |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
NEWS RELEASE – INSIDE AND REGULATED INFORMATIONAugust 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology marketProvides the most comprehensive menu of advanced molecular tests for urology in prostate cancerEnhances scale with best-in-class commercial channel into urology communityExact Sciences to take portion of initial payment i
- Globe Newswire
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director
NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2022 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EG
- Globe Newswire
Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer
NEWS RELEASE - REGULATED INFORMATIONMay 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx® for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Cov
